{
  "id": 20528869,
  "title": "Gilead Sciences CFO Dickinson sells $514,410 in stock",
  "url": "https://urgent.news/2026/11/18/gilead-sciences-cfo-dickinson-sells-514-410-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-18T01:45:47.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/gilead-sciences-cfo-dickinson-sells-514410-in-stock-93CH-5034509"
  },
  "original_language": "en",
  "account": "Andrew D. Dickinson, Gilead Sciences' Chief Financial Officer, disposed of 3,000 shares of the company's stock on November 16, 2026, for a total of $514,410. The sale was executed via a pre-approved Rule 10b5-1 trading plan, which Dickinson established on August 29, 2024. At the time of the transaction, each share was worth $171.47. The stock's price is currently trading near its 52-week peak of $176.58, following a robust 33% gain over the past six months. Despite this, analysts believe the stock may be overvalued relative to its estimated fair value. Dickinson now personally owns 158,096 shares of Gilead Sciences. The company's latest quarter saw impressive financials, with revenue of $8.3 billion, surpassing analyst estimates by 6%. Earnings per share also exceeded expectations, at $2.55, a 15% improvement over forecasts. Gilead Sciences' HIV portfolio has been a significant driver of this success, contributing to a $500 million revenue increase and prompting a $900 million increase in the company's fiscal 2026 earnings guidance. Recent analyst activity has been bullish, with firms like UBS and TD Cowen raising price targets and maintaining Buy ratings. These positive developments highlight Gilead Sciences' strong performance and promising future outlook.",
  "summary": null,
  "key_points": [
    "CFO Andrew Dickinson sold 3,000 shares of Gilead Sciences stock on November 16, 2026, for $514,410.",
    "Sale executed through pre-approved Rule 10b5-1 trading plan established on August 29, 2024.",
    "Current stock price near 52-week high of $176.58 despite analysts' concerns about overvaluation."
  ],
  "editors_take": "The CFO's pre-planned divestment during a period of peak stock pricing reflects a routine liquidity event rather than a shift in sentiment despite conflicting analyst views on valuation.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}